| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | APRE | Common Stock | Purchase | $14,764 | +4,068 | +25% | $3.63 | 20,296 | 06 Jun 2023 | Direct | F1 |
| transaction | APRE | Common Stock | Purchase | $22,192 | +6,029 | +30% | $3.68 | 26,325 | 07 Jun 2023 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.4984 to $3.75, inclusive. The reporting person undertakes to provide to Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.65 to $3.70, inclusive. The reporting person undertakes to provide to Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. |
| F3 | Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023. |
Exhibit 24 - Power of Attorney